[PRESSWIRE] Vienna, Austria - 02.05.2003 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).

PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies

Greater selectivity of PMN310 for toxic oligomers indicates a potentially differentiated profile and supports further development

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 14, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its third quarter 2022 financial results and recent highlights.

[PRESSWIRE] Austria - 04.07.22 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that, to meet the criteria to list its common shares on the Nasdaq Capital Market (“NASDAQ”), the Board of Directors has approved a 1-for-60 reverse share split (the “Reverse Split”), of the Company's issued and outstanding common shares.

[PRESSWIRE] EDMOND, OKLAHOMA - MAY 24, 2022 -- IRIS JUNE / Soon after Kosmik Brands launched in the great state of Nevada, they are back with more exciting news. Planet 13, globally recognized as the largest cannabis dispensary in the world, now carries all Kosmik products. Setting the world record with their opening back in 2018, since day one, Planet 13 continues to set the bar higher than any other facility when it comes to customer experience. Here’s what’s in store.

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

[PRESSWIRE] Greenwich, Connecticut - April 14, 2022 -- The non-profit, Freedom to Operate (FTO), has just published an open letter to Compass Pathways’ CEO, George Goldsmith, regarding the invalidity of one of Compass’ U.S. patents on psilocybin.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —March 24, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.